EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer

Ethan Abizadeh iD, Eli Berglas, Aaron Abizadeh, Julia Glatman, Aaron B Lavi, Mark Spivak, Tzuriel Sapir iD, David Shifteh iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178696 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ethan Abizadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA. Hauptthemen laut MEDLINE: Neoplasms, Phosphatidylinositol 3-Kinases, MAP Kinase Signaling System, Protein Kinase Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ERK1/2 and PI3K signaling pathways play important roles in cellular proliferation, survival, differentiation, and metabolism. In cancer, these pathways are frequently dysregulated and overactivated, resulting in poor patient prognosis and resistance to treatment. These pathways are activated by receptor tyrosine kinases and send downstream signals to effectors such as RAS, RAF, MEK, AKT, and mTOR. In this review, we highlight the key components of the ERK1/2 and PI3K pathways, the roles they play in tumor progression, and the development of inhibitors and combination therapies designed to enhance therapeutic outcomes and address treatment resistance. Our review demonstrates the need and promise for future research and clinical trials for inhibitors and combination therapies for the ERK1/2 and PI3K pathways in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPhosphatidylinositol 3-KinasesMAP Kinase Signaling SystemProtein Kinase InhibitorsAntineoplastic AgentsHumansAnimalsMolecular Targeted TherapySignal TransductionPhosphoinositide-3 Kinase Inhibitors

Stichwörter der Autor:innen

AKTEGFRERKFGFR3MEKPI3KPTENRAFRASmTOR

Substanzen

Phosphatidylinositol 3-KinasesProtein Kinase InhibitorsAntineoplastic AgentsPhosphoinositide-3 Kinase Inhibitors

Autor:innen und Institutionen

  • College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA.
  • Zucker School of Medicine, Hofstra University, Hempstead, NY 11549, USA.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Ethan Abizadeh, Tzuriel Sapir, David Shifteh

Zitieren

APA

Abizadeh, E., Berglas, E., Abizadeh, A., Glatman, J., Lavi, A. B., Spivak, M., Sapir, T., & Shifteh, D. (2025). Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178696

Vancouver

Abizadeh E, Berglas E, Abizadeh A, Glatman J, Lavi AB, Spivak M, et al. Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178696

BibTeX
@article{Abizadeh2025,
  author = {Abizadeh, Ethan and Berglas, Eli and Abizadeh, Aaron and Glatman, Julia and Lavi, Aaron B and Spivak, Mark and Sapir, Tzuriel and Shifteh, David},
  title = {Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178696}
}
Kostenlos starten →